Drug Development Pipeline
This program studied MAT2501, an oral version of the drug amikacin. Amikacin is an antibiotic that targets nontuberculous mycobacteria (NTM) infections in people with cystic fibrosis. MAT2501 was studied for the potential to reduce the risk of known amikacin side effects such as hearing loss and kidney problems.
No further development in CF is planned at this time.
This program was sponsored by Matinas BioPharma and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More